Sun Yat-sen University: Nasopharyngeal Neoplasms trials

The registry lists 38 Nasopharyngeal Neoplasms studies with Sun Yat-sen University as lead sponsor. 10 are open to participants now and 1 have results posted.

Phase 1 3Phase 2 17Phase 3 11No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Full-wrap Versus Conventional Suspension for Reducing Soft Palate Injury Rate in Transoral SurgeryNot yet recruitingNCT07552545Not applicable
• Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal CarcinomaNot yet recruitingNCT07524413Phase 3
• Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal CarcinomaNot yet recruitingNCT07385079Phase 3
• Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal CarcinomaNot yet recruitingNCT07373990Phase 3
• PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPCRecruitingNCT07332247Phase 2
• EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal CarcinomaRecruitingNCT06802835Phase 1/2
• QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.RecruitingNCT06749899Phase 3
• Adebrelimab and Chemoradiotherapy in High-risk LANPCRecruitingNCT06349889Phase 2
• Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal CarcinomaRecruitingNCT04453826Phase 3
• Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma PatientsRecruitingNCT03353467Not applicable
• To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal CancerCompletedNCT00697619Phase 2Results posted
• Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT05807880Phase 2
• Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)Active, not recruitingNCT05587374Phase 3
• Nab-paclitaxel Based TPX Neoadjuvant Chemotherapy for NPC Patients: a Dose-escalation StudyActive, not recruitingNCT04850235Phase 1
• A Study of DC-CIK Immunotherapy in the Treatment of Solid TumorsStatus unknownNCT04476641Phase 2
• IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma.Status unknownNCT03854838Phase 2
• GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal CarcinomaActive, not recruitingNCT03840421Phase 3
• Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal CarcinomaStatus unknownNCT03837808Phase 3
• Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal CarcinomaStatus unknownNCT03700476Phase 3
• PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal CarcinomaStatus unknownNCT03619824Phase 2
• PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal CarcinomaActive, not recruitingNCT03427827Phase 3
• Elimination of Adjuvant Chemotherapy for Selected Stage II and III Nasopharyngeal CarcinomaCompletedNCT03175939Phase 2
• Measuring Patient-Reported Adverse Events in Oncology Practice Improves Quality of Life in Nasopharyngeal CarcinomaStatus unknownNCT03093649Not applicable
• A Study of Nasopharyngeal Carcinoma From GuangdongStatus unknownNCT03003182
• ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following RadiotherapyTerminatedNCT02874651Phase 2
• Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation in Nasopharyngeal CarcinomaStatus unknownNCT02627807Not applicable
• The Value of Diagnosis and Outcome Prediction in CTC for Metastatic NPC PatientsCompletedNCT02505139
• Hyperfractionated Intensity-modulated Radiotherapy (IMRT) Versus Conventional Fraction IMRT for Patients With Loco-regionally Recurrent Nasopharyngeal Carcinoma.Status unknownNCT02456506Not applicable
• Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Nasopharyngeal CarcinomaCompletedNCT02360501Phase 2
• Efficacy and Safety of TC+AVASTIN Versus TC in Patients With Metastatic Nasopharyngeal CarcinomaStatus unknownNCT02250599Phase 2
• Hemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction in Nasopharyngeal CarcinomaStatus unknownNCT02211677
• A Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Different Amifostine RegimensStatus unknownNCT01762514Phase 2
• Dose-finding Study of Abraxane in Combination With Cisplatin to Treat Advanced Nasopharyngeal CarcinomaStatus unknownNCT01735409Phase 1/2
• Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal CarcinomaCompletedNCT01528618Phase 3
• Evaluating Endostatin Plus TC Regimen in Secondary Malignant Neoplasm of Liver Using Contrast Enhancement UltrasonographyStatus unknownNCT01347424Phase 2
• Cluster Randomized Controlled Screening Trial for NPCStatus unknownNCT00941538Not applicable
• Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)CompletedNCT00747799Phase 2
• Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Have Had Prior Platinum Based ChemotherapyCompletedNCT00630149Phase 2